Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Zhengzhou
Clinical trial register · China

Clinical Trials in Zhengzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 5576 Shanghai 3879 Guangzhou 3345 Hangzhou 1819 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Henan Cancer Hospital75 The First Affiliated Hospital of Zhengzhou University38 Merck Sharp & Dohme LLC28 AbbVie21 Novartis Pharmaceuticals20
Site location
Beijing5576 Shanghai3879 Guangzhou3345 Hangzhou1819 Wuhan1343
All 625 locations
Target enrolment
to

Trials with a site in Zhengzhou

931 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Remote Intervention Versus Routine Monitoring in COPD Patients With Chronic Hypercapnia Receiving Home Non-invasive Respiratory Support
NCT07751003COPD (Chronic Obstructive Pulmonary Disease), Acute Exacerbation of COPD, Hypercapnia
Sir Run Run Shaw Hospital
Not applicable
236
Zhengzhou, Changsha, Hangzhou, Wenling
2027-08-01
Not yet open
The First Affiliated Hospital of Zhengzhou University
Observational
100
Zhengzhou
2027-01-21
Recruiting
Amgen
Phase 3
180
Hefei, Beijing, Chongqing, Fuzhou, Zhengzhou, Wuhan, Nanjing, Suzhou
2026-12-18
Not yet open
Bristol-Myers Squibb
Phase 3
2,380
Hefei, Beijing, Shenzhen, Guangzhou, Shenzhen Shi, Zhengzhou, Shijiazhuang, Yichang Shi
2026-12-16
Not yet open
Shanghai MicroPort CardioFlow Medtech Co., Ltd.
Not applicable
152
Beijing, Kunming, Zhengzhou
2026-12-01
Not yet open
Traditional Chinese Medicine in Multidrug-Resistant Bacterial Pneumonia
NCT07726095Multi Drug Resistant Infections, Pneumnia
Henan University of Traditional Chinese Medicine
Observational
652
Zhengzhou
2026-12-01
Not yet open
Zhai Wenlong
Phase 3
90
Zhengzhou
2026-11-30
Not yet open
Beijing QL Biopharmaceutical Co.,Ltd
Phase 1
24
Chongqing, Zhengzhou, Chengdu
2026-11-13
Not yet open
Henan University of Traditional Chinese Medicine
Not applicable
320
Zhengzhou
2026-11-02
Not yet open
Oculomotor-Pupillary AI Biomarkers in Parkinson's
NCT07886450PARKINSON DISEASE (Disorder)
The Hong Kong Polytechnic University
Observational
128
Zhengzhou
2026-11-01
Not yet open
Efficacy of Lipoic Acid on Chronic Ischemic Heart Failure Patients
NCT07725484Heart Failure Due to Coronary Artery Disease
DrugAlpha Lipoic Acid
Shanghai Zhongshan Hospital
Phase 3
1,188
Hefei, Fuzhou, Guangzhou, Luoyang, Zhengzhou, Nanjing, Dalian, Xi'an
2026-11-01
Not yet open
China National Center for Cardiovascular Diseases
Phase 3
270
Beijing, Guangzhou, Shenzhen, Zhangjiakou, Xinxiang, Zhengzhou, Wuhan, Baotou
2026-11-01
Recruiting
CHRONO-MOBILIZE: Chronotherapy of G-CSF for CD34+ Mobilization in Healthy Donors
NCT07423728Granulocyte Colony-Stimulating Factor (G-CSF) Mobilization
DrugG-Csf
First Affiliated Hospital of Zhejiang University
Not applicable
160
Zhengzhou, Wuhan, Hangzhou
2026-11-01
Not yet open
Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer
NCT07781150Obesity, Overweight, Atypical Endometrial Hyperplasia, Endometrial Carcinoma Stage I
DrugMazdutide
Tongji Hospital
Phase 2
128
Zhengzhou, Wuhan, Changchun, Hangzhou, Shanghai, Tianjin
2026-11-01
Not yet open
Henan Cancer Hospital
Phase 2
155
Zhengzhou
2026-11-01
Not yet open
The First Affiliated Hospital of Zhengzhou University
Phase 2
34
Zhengzhou
2026-11
Not yet open
EEG Feedback-Based Vagus Nerve Stimulation for Post-Stroke Dysphagia
NCT07894315Ischemic Stroke, Post-stroke Dysphagia, Swallowing Disorders
First Affiliated Hospital of Fujian Medical University
Not applicable
60
Fuzhou, Zhangzhou, Zhengzhou, Xi'an, Beijing
2026-11
Not yet open
Bisirna Therapeutics (Suzhou) Co., Ltd.
Phase 3
70
Beijing, Jilin City, Quanzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2026-10-29
Recruiting
Pfizer
Phase 3
432
Hefei, Beijing, Huizhou, Zhengzhou, Nanjing, Nanchang
2026-10-28
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
184
Beijing, Fuzhou, Lanzhou, Guangzhou, Guiyang, Baoding, Harbin, Zhengzhou
2026-10-22
Not yet open
Remimazolam vs Propofol for Long-Term Sedation in Mechanically Ventilated ICU Patients
NCT07880548Long-term Sedation for Mechanical Ventilation, Critically Ill Intensive Care Unit Patients
Sun Yat-sen University
Phase 3
274
Dongguan, Guangzhou, Shenzhen, Nanning, Luoyang, Zhengzhou, Wuhan, Nantong
2026-10-20
Not yet open
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
64
Beijing, Lanzhou, Foshan, Nanning, Harbin, Zhengzhou, Wuhan, Changsha
2026-10-20
Recruiting
Wecare Probiotics Co., Ltd.
Not applicable
100
Zhengzhou
2026-10-14
Recruiting
Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure
NCT07575672HFpEF - Heart Failure With Preserved Ejection Fraction, TAVI(Transcatheter Aortic Valve Implantation), Finerenone
DrugFinerenone
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
2,832
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Zhengzhou
2026-10-09
Recruiting
Bristol-Myers Squibb
Phase 1/2
84
Beijing, Guangzhou, Zhengzhou, Nanchang, Shanghai
2026-10-06
Recruiting
AstraZeneca
Observational
300
Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Yantai, Shanghai, Taiyuan
2026-10-01
Recruiting
Yongquan Shi
Phase 4
448
Zhengzhou, Xi'an, Wenzhou, Beijing, Chongqing, Foshan, Fujian, Guangzhou
2026-10-01
Not yet open
Clinical Evaluation of a Novel DAB Chromogenic Tissue-Based Assay for Detecting Anti-GABABR Antibodies
NCT07858175Autoimmune Encephalitis, Anti-NMDAR Encephalitis, Anti-GABABR Encephalitis
Third Affiliated Hospital, Sun Yat-Sen University
Observational
300
Guangzhou, Zhengzhou
2026-10
Not yet open
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
280
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan
2026-10
Not yet open
Henan Cancer Hospital
Observational
147
Zhengzhou
2026-10
Not yet open
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
440
Zhengzhou
2026-10
Not yet open
Henan Cancer Hospital
Phase 2
35
Zhengzhou
2026-09-30
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
80
Beijing, Guangzhou, Zhengzhou, Wuhan, Xianning, Jinan, Shanghai, Luzhou
2026-09-29
Recruiting
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
NCT07732309Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Sjogren's Disease, Autoimmune Diseases
Antengene Biologics Limited
Phase 1
149
Bengbu, Hefei, Beijing, Xiamen, Guangzhou, Luoyang, Zhengzhou, Wuhan
2026-09-26
Recruiting
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Beijing, Chengdu, Guangdong Province, Guangzhou, Hangzhou, Nanchang, Wuhan, Zhengzhou
2026-09-24
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 4
50
Fuyang, Zhengzhou, Zhoukou, Huaian, Yancheng, Meihekou, Shanghai
2026-09-23
Recruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2
84
Beijing, Zhengzhou
2026-09-07
Recruiting
Shanghai UniXell Biotechnology Co., Ltd
Phase 1
12
Beijing, Zhengzhou, Chengdu
2026-09-05
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
23
Zhengzhou, Changsha, Nanchang, Guangzhou, Nanjing, Wuhan
2026-09-01
Not yet open
Study of SG301 for Renal AMR After Transplantation
NCT07764627Antibody Mediated Rejection
DrugSG301
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
10
Guangzhou, Nanning, Zhengzhou, Changsha, Jinan, Chengdu, Hangzhou
2026-09-01
Not yet open
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke
NCT07466251Acute Ischemic Stroke AIS, Intracranial Atherosclerosis ICAS, Atherosclerotic Plaque
DrugRecaticimab
Peking Union Medical College Hospital
Phase 4
1,212
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2026-09-01
Recruiting
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
222
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Shenyang, Xi'an, Jinan
2026-09
Not yet open
Yiqi Fumai Lyophilized Injection for Chronic Heart Failure Caused by Coronary Heart Disease
NCT07803471Chronic Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF), Coronary Heart Disease (CHD)
DrugYiqi Fumai
China Academy of Chinese Medical Sciences
Not applicable
100
Guangzhou, Zhengzhou, Jinan, Tianjin
2026-09
Not yet open
The First Affiliated Hospital of Zhengzhou University
Observational
500
Guangzhou, Zhengzhou, Shanghai, Chengdu, Tianjin, Kunming
2026-09
Recruiting
Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration
NCT07776522Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
DrugAflibercept
West China Hospital
Phase 2
50
Beijing, Jilin City, Chongqing, Shantou, Zhejiang, Harbin, Zhengzhou, Wuhan
2026-08-31
Not yet open
The First Affiliated Hospital of Zhengzhou University
Phase 2
88
Zhengzhou
2026-08-31
Not yet open
Zhai Wenlong
Phase 4
40
Zhengzhou
2026-08-30
Not yet open
Sun Yat-sen University
Phase 2
40
Guangzhou, Shijiazhuang, Anyang, Zhengzhou, Nanjing, Nanchang, Dalian, Chengdu
2026-08-28
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
145
Hefei, Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Shanghai
2026-08-25
Not yet open
VelaVigo Bio Inc
Phase 1/2
260
Zhejiang, Zhengzhou, Changsha, Nanchang, Shengyang, Shanghai, Taiyuan
2026-08-24
Not yet open
TCM Cohort for Elderly COPD
NCT07780682Chronic Obstructive Pulmonary Disease (COPD)
Henan University of Traditional Chinese Medicine
Observational
2,386
Zhengzhou
2026-08-20
Not yet open
TCM Cohort for Elderly CAP
NCT07797686Community-acquired Pneumonia (CAP)
Henan University of Traditional Chinese Medicine
Observational
2,234
Zhengzhou
2026-08-20
Not yet open
Nanjing IASO Biotechnology Co., Ltd.
Phase 1/2
27
Beijing, Zhengzhou, Shanghai, Hangzhou
2026-08-15
Recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 2
160
Beijing, Zhengzhou
2026-08-14
Recruiting
Chengdu Kangnuoxing Biopharma,Inc.
Phase 3
136
Beijing, Langfang, Baoding, Cangzhou, Shijiazhuang, Zhangjiakou, Zhengzhou, Baotou
2026-08-13
Recruiting
SMP-656 for HER2-Positive Advanced Breast Cancer
NCT07726342HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
Chengdu SciMount Pharmatech Co., Ltd.
Phase 2
60
Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Nanjing
2026-08-10
Recruiting
Beijing Tiantan Hospital
Observational
3,000
Beijing, Zhengzhou, Wuhan, Suzhou, Nanchang, Shanghai, Chengdu, Hangzhou
2026-08-03
Not yet open
Hangzhou PhecdaMed Co., Ltd.
Phase 3
300
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Suzhou, Shanghai
2026-08-03
Not yet open
Evaluation of NWRD09 for HPV-16 Related Cervical HSIL
NCT07712692High-grade Squamous Intraepithelial Lesion (HSIL)
DrugNWRD09
Newish Biotech (Wuxi) Co., Ltd.
Phase 2
156
Beijing, Chongqing, Lanzhou, Baoding, Zhengzhou, Nanjing, Changchun, Jinan
2026-08-01
Not yet open
Xuanwu Hospital, Beijing
Not applicable
368
Beijing, Zhengzhou, Wuhan
2026-08-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
128
Zhengzhou, Nanjing
2026-08
Not yet open
Shenzhen Fosun Kairos Biotechnology Co., Ltd.
Phase 1/2
32
Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Jinan, Shanghai, Chengdu
2026-08
Recruiting
Tianjin Medical University Cancer Institute and Hospital
Phase 2
120
Beijing, Zhengzhou, Shenyang, Taiyuan, Chengdu, Tianjin
2026-07-31
Recruiting
Zhai Wenlong
Phase 4
90
Zhengzhou
2026-07-30
Recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
675
Zhengzhou, Nanjing
2026-07-24
Recruiting
Sichuan Huiyu Pharmaceutical Co., Ltd
Phase 1
88
Zhengzhou
2026-07-23
Recruiting
Henan Cancer Hospital
Phase 2
200
Zhengzhou
2026-07-17
Recruiting
PEI-GT Trial for Initial Treatment of Primary Open-Angle Glaucoma With Cataract
NCT07700498Primary Open Angle Glaucoma and Cataracts
Nanfang Hospital, Southern Medical University
Not applicable
106
Ningxia, Guangzhou, Luzhou, Zhengzhou, Zhuhai
2026-07-15
Recruiting
Polypills Approach for Multiple Cardiovascular Risk Factors
NCT07679828Hypertension, Dyslipidemia, Diabetes
China Medical University, China
Not applicable
8,252
Zhengzhou, Chifeng, Tongliao, Kunshan, Suzhou, Taizhou, Jinzhou, Panjin
2026-07-11
Not yet open
Henan Cancer Hospital
Phase 2
75
Zhengzhou
2026-07-10
Recruiting
Avistone Biotechnology Co., Ltd.
Phase 1/2
294
Guangzhou, Harbin, Zhengzhou, Chengdu
2026-07-10
Recruiting
Ausper Biopharma Co., Ltd.
Phase 1
32
Chongqing, Zhengzhou, Shanghai, Chengdu, Hangzhou
2026-07-09
Recruiting
Hoffmann-La Roche
Phase 3
300
Zhengzhou, Xianyang, Ningbo, Beijing, Changchun, Hefei, Herbin, Huai'an
2026-07-03
By invitation
Jiangsu Chuangyuan Life Science and Technology Co., Ltd.
Phase 1
74
Beijing, Zhengzhou, Nanjing
2026-07-03
Recruiting
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Phase 1
202
Zhengzhou
2026-07-03
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
472
Fuzhou, Zhengzhou, Changsha, Shenyang, Jinan, Hangzhou
2026-07-03
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
DrugPF-08634404
Pfizer
Phase 2
40
Beijing, Fuzhou, Zhengzhou, Wuhan, Nanchang, Shanghai, Hangzhou
2026-07-02
Not yet open
Zishen Yutai Pill for Patients With Recurrent Implantation Failure
NCT07641088Recurrent Implantation Failure
Peking University Third Hospital
Not applicable
878
Hefei, Beijing, Guangzhou, Shijiazhuang, Zhengzhou, Changsha, Nanjing, Xi'an
2026-07-01
Not yet open
Children's Hospital of Fudan University
Not applicable
200
Xiamen, Guangzhou, Zhengzhou, Jinan, Shanghai
2026-07-01
Recruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2
108
Nanjing, Hangzhou, Ha’erbin, Huai'an, Zhengzhou
2026-07-01
Not yet open
Yanyan Liu
Observational
200
Zhengzhou
2026-07
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
127
Beijing, Lanzhou, Guangzhou, Anyang, Luoyang, Zhengzhou, Nanjing, Xuzhou
2026-07
Not yet open
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
240
Zhengzhou
2026-07
By invitation
Compassionate Administration of ZVS101e for Extended Treatment
NCT07307469Bietti Crystalline Corneoretinal Dystrophy
DrugZVS101e
Chigenovo Co., Ltd
Not applicable
32
Beijing, Guangzhou, Zhengzhou, Chengdu, Tianjin
2026-07
Not yet open
Peking University
Not applicable
480
Wuhu, Zhengzhou, Shenyang, Zibo, Shanghai, Hangzhou, Jinhua, Beijing
2026-07
Not yet open
Henan Cancer Hospital
Phase 2
45
Zhengzhou
2026-06-30
Recruiting
Study of AHB-171 in Chronic Hepatitis B Participants
NCT07630727Hepatitis B, Chronic (CHB)
DrugAHB-171
Ausper Biopharma Co., Ltd.
Phase 2
138
Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Changzhou, Jilin City
2026-06-24
Recruiting
BeOne Medicines
Phase 1
118
Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin
2026-06-23
Recruiting
Vantive Health LLC
Observational
750
Beijing, Chongqing, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha
2026-06-17
Recruiting
Henan Cancer Hospital
Phase 3
1,044
Zhengzhou
2026-06-16
Not yet open
Shanghai Best-Link Bioscience, LLC
Phase 1
33
Harbin, Zhengzhou, Wuhan, Changzhou, Shenyang, Taizhou, Shanghai
2026-06-16
Recruiting
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
562
Zhengzhou, Shanghai
2026-06-15
Recruiting
Hefei Xinzhu Biological Technology Co., Ltd.
Phase 1/2
114
Changsha, Shanghai, Zhengzhou
2026-06-15
Not yet open
Yi Shuhua
Phase 2
60
Shenzhen, Zhengzhou, Changsha, Nanjing, Nanchang, Jinan, Tianjin
2026-06-08
Recruiting
Takeda
Phase 2
92
Beijing, Guangzhou, Zhengzhou
2026-06-04
Not yet open
The First Affiliated Hospital of Zhengzhou University
Phase 3
586
Zhengzhou
2026-06-01
Not yet open
Philips Clinical & Medical Affairs Global
Observational
200
Zhengzhou
2026-06-01
Recruiting
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
NCT06712654Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
R1 Therapeutics
Phase 2
168
Beijing, Zhengzhou, Nanjing, Shanghai, Chengdu
2026-06-01
Recruiting
Shanghai Zhongshan Hospital
Observational
333
Beijing, Guangzhou, Shenzhen, Naning, Harbin, Zhengzhou, Wuhan, Nanjing
2026-06
Not yet open
Biotech Pharmaceutical Co., Ltd.
Phase 1
60
Chongqing, Zhengzhou, Changsha, Nanjing, Xi'an, Shanghai, Taiyuan, Chengdu
2026-05-30
By invitation
Changchun BCHT Biotechnology Co.
Phase 1
120
Zhengzhou
2026-05-28
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Hefei, Beijing, Fuzhou, Xiamen, Shijiazhuang, Zhengzhou, Shiyan, Wuhan
2026-05-28
Recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.
Phase 1
24
Zhengzhou
2026-05-26
Recruiting
AbbVie
Phase 3
990
Beijing, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan, Wuxi, Changchun
2026-05-22
Recruiting
Chinese Adults With Kidney Disease
NCT07522099Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), IC-MPGN
DrugTelitacicept
ADARx Pharmaceuticals, Inc.
Phase 2
30
Shenzhen, Guiyang, Zhengzhou, Baotou, Wuxi, Yantai, Beijing, Shandong
2026-05-21
Recruiting
Henan Provincial People's Hospital
Not applicable
196
Zhengzhou
2026-05-21
Recruiting
Huahui Health
Phase 1/2
30
Bengbu, Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou
2026-05-19
Not yet open
Foresight Therapeutics (Hefei) Co., Ltd.
Phase 1
156
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Changchun
2026-05-15
Recruiting
FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis
NCT07511309Atherosclerotic Renal Artery Stenosis, Fractional Flow Reserve, Optimal Medical Therapy, Stent Implantation
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
300
Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Dalian, Changchun, Jinan
2026-05-15
Recruiting
Ipsen
Phase 3
350
Beijing, Guangzhou, Zhengzhou, Nanchang, Changchun, Jinan, Shanghai, Tianjin
2026-05-14
Recruiting
RemeGen Co., Ltd.
Phase 2/3
80
Beijing, Chongqing, Fuzhou, Meizhou, Nanjing, Shijiazhuang, Zhengzhou, Wuhan
2026-05-12
Active, closed
Yongxu Jia
Phase 2
34
Zhengzhou
2026-05-10
Recruiting
Mirati Therapeutics Inc.
Phase 2
170
Beijing, Xiamen, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang, Jinan
2026-05-06
Not yet open
Henan Cancer Hospital
Phase 2
50
Zhengzhou
2026-05-05
Recruiting
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
NCT07519772Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
DrugMK-1045
Merck Sharp & Dohme LLC
Phase 1/2
280
Beijing, Fuzhou, Guangzhou, Zhengzhou, Shanghai
2026-05-03
Not yet open
X-ray Assisted Diagnostic System
NCT07497243Chest X-ray for Clinical Evaluation
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
16,000
Wuhan, Zhengzhou
2026-05-01
Not yet open
Phosphate-Containing Replacement Fluid for Patients Undergoing CRRT
NCT07550894Acute Kidney Injury, Sepsis, Critically Ill Patients Requiring Continuous Renal Replacement Therapy
Sun Yat-sen University
Phase 3
220
Chongqing, Guangzhou, Nanning, Luoyang, Zhengzhou, Wuhan, Nanjing, Xi'an
2026-05-01
Not yet open
UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma
NCT07500805CD70-positive Advanced Renal Clear Cell Carcinoma
UTC Therapeutics Inc.
Phase 1
21
Zhengzhou
2026-05-01
Not yet open
Clinical Study on the Preservation of Ovarian Function Following Hematopoietic Stem Cell Transplantation in Patients With Malignant Hematologic Diseases Using Goserelin
NCT07552480Allogeneic Haematopoietic Stem Cell Transplantation, Malignant Hematologic Disease, Ovarian Insufficiency
DrugGoserelin
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
64
Zhengzhou, Wuhan, Kunming, Hangzhou
2026-05-01
Not yet open
The First Affiliated Hospital of Zhengzhou University
Phase 3
564
Zhengzhou
2026-05-01
Not yet open
Clinical Study on the Preservation of Ovarian Function in Patients With Aplastic Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation Using Goserelin
NCT07552506Aplastic Anaemia (AA), Allogeneic Haematopoietic Stem Cell Transplantation, Ovarian Insufficiency
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
132
Zhengzhou, Wuhan, Kunming, Hangzhou
2026-05-01
Not yet open
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Not applicable
64
Zhengzhou, Wuhan, Kunming, Hangzhou
2026-05-01
Recruiting
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Phase 1/2
120
Beijing, Jilin City, Fuzhou, Xiamen, Lanzhou, Guangzhou, Guiyang, Zhengzhou
2026-04-30
Not yet open
Covered vs Bare Metal Stents for Atherosclerotic Renal Artery Stenosis
NCT07566065Atherosclerotic Renal Artery Stenosis, Hypertension, Renal Artery Stenosis
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
150
Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Dalian, Jinan, Qingdao
2026-04-30
Recruiting
Biogen
Phase 3
30
Zhengzhou, Guangzhou, Shanghai
2026-04-28
Recruiting
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
NCT07354074Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive
DrugsAsciminib single agent·ABL001
Novartis Pharmaceuticals
Phase 2
50
Zhengzhou, Tianjin
2026-04-28
Recruiting
Bayer
Phase 2
250
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2026-04-27
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
105
Hefei, Beijing, Chongqing, Fuzhou, Dongguan, Guangzhou, Shijiazhuang, Zhengzhou
2026-04-27
Active, closed
Shandong Suncadia Medicine Co., Ltd.
Phase 2
61
Chongqing, Zhengzhou
2026-04-23
Recruiting
Daoyin Technique for Improving Exercise Endurance in IPF
NCT07019714Idiopathic Pulmonary Fibrosis
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Not applicable
236
Beijing, Zhengzhou, Shenyang
2026-04-22
Recruiting
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1/2
40
Zhengzhou, Suzhou, Xi’an, Hangzhou
2026-04-16
Recruiting
Xuanwu Hospital, Beijing
Not applicable
264
Beijing, Fuzhou, Shijiazhuang, Harbin, Nanyang, Zhengzhou, Baotou, Xi'an
2026-04-15
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
27
Shenzhen, Zhengzhou, Nanchang, Jinan, Tianjin
2026-04-15
Recruiting
Dizal Pharmaceuticals
Phase 1/2
220
Chongqing, Fuzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Chengdu, Taizhou
2026-04-15
Recruiting
A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma
NCT07493135Relapsed/Refractory Multiple Myeloma
Suzhou Immunofoco Biotechnology Co., Ltd
Early Phase 1
30
Beijing, Chongqing, Shanghai, Zhengzhou
2026-04-14
Recruiting
Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery
NCT07229495Scoliosis; Adolescence, Pain After Surgery, Analgesia, Patient-controlled
DrugsTegileridine·Morphine
Peking Union Medical College Hospital
Phase 4
171
Zhengzhou, Nanchang, Beijing, Shanghai
2026-04-08
Recruiting
Lepu Biopharma Co., Ltd.
Phase 1/2
160
Beijing, Fuzhou, Zhengzhou, Nanjing, Tianjin, Lishui
2026-04-08
Recruiting
First Affiliated Hospital Xi'an Jiaotong University
Phase 3
820
Lanzhou, Shijiazhuang, Zhengzhou, Loudi, Dalian, Xining, Xi'an, Taiyuan
2026-04-07
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Beijing, Harbin, Zhengzhou
2026-04-02
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
33
Beijing, Chongqing, Guangdong, Harbin, Zhengzhou, Wuhan, Changsha, Changchun
2026-04-02
Not yet open
yilong Wang
Not applicable
86
Beijing, Kaifeng, Xinxiang, Zhengzhou, Linyi, Tianjin
2026-04-01
Not yet open
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
24
Xiamen, Zhengzhou, Qingdao
2026-04
Recruiting
NK Cell Therapy for Malignant Solid Brain Tumors
NCT07552233Malignant Solid Brain Tumors, Glioblastoma (GBM), Glioblastoma Multiforme (GBM), Brain Metastasis
Peking University Third Hospital
Not applicable
27
Beijing, Qinhuangdao, Zhengzhou
2026-04
Not yet open
The First Affiliated Hospital of Zhengzhou University
Phase 3
578
Zhengzhou
2026-04
Recruiting
Fujian Medical University
Not applicable
1,312
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Dalian
2026-03-29
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
60
Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Jinan, Hangzhou
2026-03-27
Recruiting
Eisai Inc.
Phase 2
64
Beijing, Changchun, Guangdong, Guangzhou, Jinan, Nanchang, Shanghai, Zhengzhou
2026-03-26
Recruiting
Amgen
Phase 3
406
Beijing, Zhengzhou, Changsha, Nanjing, Yinchuan, Xi'an, Jinan
2026-03-23
Not yet open
Dermavon Holdings Limited
Phase 2
160
Beijing, Fuzhou, Guangzhou, Shenzhen, Haikou, Shijiazhuang, Tangshan, Zhengzhou
2026-03-20
Recruiting
Radiotherapy After Prostatectomy for Node Positive Prostate Cancer
NCT07477626Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic, Androgen Deprivation Therapy
Sun Yat-sen University
Phase 3
372
Dongguan, Guangzhou, Zhanjiang, Zhengzhou, Chengdu, Hangzhou, Beijing, Shanghai
2026-03-20
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
300
Beijing, Chongqing, Baoding, Cangzhou, Langfang, Shijiazhuang, Zhangjiakou, Zhengzhou
2026-03-19
Recruiting
Bristol-Myers Squibb
Phase 3
850
Beijing, Chongqing, Fuzhou, Shantou, Shenzhen, Zhengzhou, Jingzhou, Wuhan
2026-03-16
Recruiting
United Innomed(Shanghai) Limited
Not applicable
330
Fuzhou, Lanzhou, Guangzhou, Guiyang, Zhengzhou, Changsha, Nanchang, Shanghai
2026-03-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Weihui, Zhengzhou, Wuhan
2026-03-13
Recruiting
Beijing Tiantan Hospital
Not applicable
376
Dongguan, Guangdong, Zhengzhou, Jinan, Jining, Ningbo, Beijing
2026-03-13
Recruiting
Effect of EIT-guided PEEP in ARDS Patients
NCT06990477ARDS (Acute Respiratory Distress Syndrome)
Southeast University, China
Not applicable
2,400
Hefei, Shanghai, Guangzhou, Zhengzhou, Hangzhou, Nanjing, Xuzhou, Nanchang
2026-03-13
Recruiting
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
NCT07424833Relapsed/Refractory Hematological Malignancies, Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL, Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation), Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Ascentage Pharma Group Inc.
Phase 1
180
Zhengzhou
2026-03-10
Not yet open
Henan Cancer Hospital
Observational
20
Zhengzhou
2026-03-10
Recruiting
ART Trial: Transcatheter J-VALVE Versus Surgery for Aortic Regurgitation Therapy
NCT07453407Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,250
Hefei, Beijing, Fuzhou, Guangzhou, Zhengzhou, Hong Kong, Wuhan, Changsha
2026-03-05
Recruiting
Hutchmed
Phase 1/2
186
Changchun, Changsha, Jinan, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou
2026-03-04
Recruiting
Shanghai Ark Biopharmaceutical Co., Ltd.
Phase 2/3
290
Beijing, Guangzhou, Cangzhou, Nanyang, Zhengzhou, Wuhan, Hangzhou, Rui’an
2026-03-03
Not yet open
AI Models in Clinical Pathology Diagnosis: A Multicenter RCT
NCT07408167Pathology Foundation Model
Nanfang Hospital, Southern Medical University
Not applicable
2,060
Chongqing, Guangzhou, Zhengzhou
2026-03-01
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 3
186
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Hangzhou
2026-03-01
Not yet open
The First Affiliated Hospital of Zhengzhou University
Phase 1/2
50
Zhengzhou
2026-03
Not yet open
Sir Run Run Shaw Hospital
Not applicable
206
Bengbu, Beijing, Nanning, Haikou, Zhengzhou, Zhoukou, Chenzhou, Huai'an
2026-03
Not yet open
Coronary Artery Drug-Coated Balloon Dilatation Catheter Clinical Trial Protocol
NCT07415902In-Stent Restenosis or De Novo Coronary Artery Lesions
DK Medical Technology (Suzhou) Co., Ltd.
Observational
252
Zhengzhou
2026-02-28
Recruiting
InxMed (Shanghai) Co., Ltd.
Phase 1/2
92
Beijing, Fuzhou, Guangzhou, Zhengzhou, Luoyang, Changsha, Nanjing, Shengyang
2026-02-28
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 2
110
Beijing, Anyang, Luoyang, Zhengzhou, Jinan, Suining
2026-02-26
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
66
Guangzhou, Zhengzhou, Chengdu, Luzhou, Hangzhou
2026-02-26
Recruiting
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2
45
Guangzhou, Zhengzhou, Chengdu
2026-02-26
Recruiting
Durvalumab as Consolidation for Patients LS-SCLC
NCT07055581Small Cell Lung Cancer Limited Stage
DrugsRadiochemotherapy·Durvalumab
Qian Chu
Phase 2
100
Zhengzhou, Wuhan
2026-02-24
Not yet open
Shenzhen Kexing Pharmaceutical Co., Ltd.
Phase 1
48
Beijing, Guiyang, Zhengzhou, Nanchang, Hangzhou
2026-02-12
Not yet open
Shanghai Pulmonary Hospital, Shanghai, China
Observational
14,300
Shijiazhuang, Zhengzhou, Changchun, Shenyang, Shanghai, Kunming
2026-02-05
Recruiting
First Affiliated Hospital of Zhejiang University
Phase 2
111
Harbin, Hefei, Shanghai, Xi'an, Zhengzhou
2026-02-01
Not yet open
The Hong Kong Polytechnic University
Not applicable
60
Zhengzhou
2026-02-01
Recruiting
Genmab
Phase 2
240
Shanghai, Beijing, Changchun, Nanjing, Tianjin, Zhangjiakou, Zhengzhou
2026-01-30
Active, closed
HS-20093 in Patients With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
NCT07462923Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
DrugRis-Rez
Hansoh BioMedical R&D Company
Phase 1
40
Beijing, Fuzhou, Xiamen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha
2026-01-29
Recruiting
Johnson & Johnson Medical (Shanghai) Ltd.
Observational
200
Chenzhou, Guangzhou, Nanjing, Nanyang, Taiyuan, Wuhu, Zhengzhou
2026-01-28
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
220
Guangzhou, Harbin, Zhengzhou, Nanjing, Changchun, Shenyang
2026-01-27
Recruiting
Effects of Enteral Feeding Regimens on NEC, Mortality, and Neurodevelopment in Very Preterm Infants
NCT07045844Very Preterm Infant, Necrotizing Enterocolitis (NEC)
The Children's Hospital of Zhejiang University School of Medicine
Not applicable
2,324
Guilin, Yulin, Zhengzhou, Wuhan, Yiyang, Hohhot, Ganzhou, Yinchuan
2026-01-23
Recruiting
BeOne Medicines
Phase 3
500
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Harbin, Zhengzhou
2026-01-22
Recruiting
G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplantation
NCT07362810Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB), Hematopoetic Stem Cell Transplantation, Hemato-oncologic Patients
DrugG-Csf
Fudan University
Phase 2
224
Fuzhou, Zhengzhou, Nanchang, Shanghai, Hangzhou
2026-01-22
Recruiting
Henan Cancer Hospital
Phase 2
92
Zhengzhou
2026-01-20
Recruiting
A Phase II Study of SKB571 in Patients With Lung Cancer
NCT07230405Lung Cancer (Non-Small Cell)
DrugSKB571
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
295
Guangzhou, Zhengzhou
2026-01-19
Not yet open
Henan University of Traditional Chinese Medicine
Not applicable
400
Zhengzhou, Jinan, Hangzhou
2026-01-15
Recruiting
Bristol-Myers Squibb
Observational
500
Beijing, Guangzhou, Jiazhuang, Zhengzhou, Suzhou, Changchun, Dalian, Xi'an
2026-01-15
Active, closed
Viatris Pharmaceuticals Co., Ltd.
Phase 2
15
Guangzhou, Shijiazhuang, Luoyang, Zhengzhou, Jiujiang, Nanchang, Beijing
2026-01-14
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Early Phase 1
38
Zhengzhou, Wuhan, Xuzhou, Nanchang, Beijing, Tianjin
2026-01-10
Recruiting
Shanghai SciBrunch Therapeutics Co., Ltd.
Phase 1/2
210
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Xuzhou, Shenyang
2026-01-08
Recruiting
Novo Nordisk A/S
Phase 3
460
Beijing, Zhengzhou, Wuhan, Changchun, Jinan, Shanghai, Chengdu
2026-01-08
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Guangzhou, Zhengzhou, Wuhan, Xiangyang, Changsha, Nanjing, Nantong, Nanchang
2026-01-05
Not yet open
Beijing Children's Hospital
Not applicable
2,650
Beijing, Chongqing, Guangzhou, Baoding, Zhengzhou, Wuxi, Changchun, Xi'an
2026-01-01
Not yet open
The First Affiliated Hospital of Zhengzhou University
Not applicable
204
Zhengzhou
2026-01-01
Not yet open
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4
174
Beijing, Foshan, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Jilin City
2026-01-01
Recruiting
Cardiovascular Outcomes and Risk Evaluation Among Recipients of Hematopoietic Stem Cell Transplantation
NCT07349498Hematopoietic Stem Cell Transplantation, Transplant Complication, Cardiovascular Events
Peking University People's Hospital
Observational
10,000
Beijing, Chongqing, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Xi'an
2026-01-01
Not yet open
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Not applicable
364
Chongqing, Foshan, Zhengzhou, Wuhan, Shenyang, Guilin, Xi’an
2026-01-01
Not yet open
TransThera Sciences (Nanjing), Inc.
Phase 3
138
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2026-01
Not yet open
Zhengzhou University
Phase 4
30
Zhengzhou
2025-12-31
Recruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
400
Zhengzhou
2025-12-31
Recruiting
Active Surveillance and Safety/Efficacy Evaluation of Innovative Devices for Structural Heart Disease Intervention
NCT07848152Transcatheter Mitral Valve Edge-to-Edge Repair System, Biodegradable Patent Foramen Ovale Closure Device
Shanghai Jiao Tong University School of Medicine
Observational
2,200
Lanzhou, Guangzhou, Zhengzhou, Wuhan, Shenyang, Jinan, Chengdu, Kunming
2025-12-30
Recruiting
Sun Yat-sen University
Phase 2
80
Guangzhou, Zhengzhou
2025-12-30
Not yet open
The First Affiliated Hospital of Zhengzhou University
Phase 2
30
Zhengzhou
2025-12-30
Recruiting
Suzhou Immunofoco Biotechnology Co., Ltd
Early Phase 1
30
Beijing, Zhengzhou, Hangzhou
2025-12-29
Recruiting
Shenzhen Majory Biotechnology Co., Ltd.
Phase 1/2
45
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou
2025-12-24
Recruiting
GenSci143 in Participants With Advanced Solid Tumors
NCT07252414Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
180
Zhengzhou, Wuhan, Changsha, Nanjing, Jinan, Shanghai, Taiyuan, Hangzhou
2025-12-20
Recruiting
NucMito Pharmaceuticals Co. Ltd.
Phase 1
30
Xiamen, Guangzhou, Zhengzhou
2025-12-18
Recruiting
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2
92
Beijing, Fuzhou, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Changchun
2025-12-16
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
42
Beijing, Guangzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Dalian, Jinan
2025-12-16
Recruiting
Hutchmed
Phase 1/2
147
Beijing, Changsha, Guangzhou, Hefei, Shanghai, Shenyang, Zhengzhou
2025-12-16
Not yet open
Chunyan Ma
Observational
1,740
Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou, Nanjing, Nanchang, Changchun
2025-12-15
Recruiting
Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer
NCT07127822Gastric / Gastroesophageal Junction Adenocarcinoma, MSI-H Cancer
DrugIparomlimab and Tuvonralimab
Peking University
Phase 2
106
Shijiazhuang, Harbin, Zhengzhou, Nanjing, Xi'an, Qingdao, Taiyuan, Chengdu
2025-12-15
Active, closed
MAXVAX Biotechnology Limited Liability Company
Phase 3
12,000
Shijiazhuang, Zhengzhou, Wuhan, Kunming
2025-12-15
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Early Phase 1
36
Zhengzhou, Nanjing, Xuzhou, Shanghai, Xi’an
2025-12-10
Recruiting
Changhai Hospital
Not applicable
376
Chongqing, Guangzhou, Shenzhen, Kaifeng, Zhengzhou, Changsha, Suzhou, Nanchang
2025-12-10
Not yet open
Abbisko Therapeutics Co, Ltd
Phase 1/2
110
Beijing, Zhengzhou, Wuhan, Shanghai, Chengde, Chengdu, Hangzhou
2025-12-10
Recruiting
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
NCT07371663Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer, Endometrial Cancer
Beijing Tide Pharmaceutical Co., Ltd
Phase 1/2
266
Beijing, Zhengzhou, Hangzhou
2025-12-03
Recruiting
Bristol-Myers Squibb
Phase 3
366
Beijing, Guangzhou, Shenzhen, Handan, Zhengzhou, Changsha, Jinan, Shanghai
2025-12-03
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
180
Beijing, Fuzhou, Guangzhou, Harbin, Anyang, Zhengzhou, Xuzhou, Shenyang
2025-12-02
Recruiting
Central China Fuwai Hospital of Zhengzhou University
Not applicable
738
Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Qingdao
2025-12-01
Recruiting
A Study on Integrated Chinese and Western Medicine for Severe Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacterial Infections
NCT07206745Severe Pneumonia Caused by Multidrug-resistant Gram-negative Bacterial Infection
Henan University of Traditional Chinese Medicine
Not applicable
152
Zhengzhou
2025-12-01
Not yet open
First Hospital of China Medical University
Observational
2,640
Chongqing, Shenzhen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Xiangyang, Changchun
2025-12
By invitation
Efficacy of Three Gingival Displacement Methods
NCT07282977Tooth Defect, Teeth Restoration
Henan Provincial People's Hospital
Not applicable
39
Zhengzhou
2025-12
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
Hefei, Fuzhou, Xiamen, Guangzhou, Naning, Heilongjiang, Shijiazhuang, Zhengzhou
2025-11-30
Recruiting
Henan Provincial People's Hospital
Not applicable
80
Zhengzhou
2025-11-30
Recruiting
Henan Genuine Biotech Co., Ltd.
Phase 1/2
110
Beijing, Changsha, Jinan, Xiamen, Zhengzhou
2025-11-27
Recruiting
AbbVie
Phase 2
180
Beijing, Zhengzhou, Wuhan, Nanchang, Shanghai, Chengdu
2025-11-25
Active, closed
Qilu Pharmaceutical Co., Ltd.
Phase 3
146
Bengbu, Beijing, Chongqing, Lanzhou, Haikou, Zhengzhou, Changsha, Nanjing
2025-11-21
Recruiting
TJ Biopharma Co., Ltd.
Phase 3
30
Beijing, Guangzhou, Nanning, Shijiazhuang, Zhengzhou, Wuhan, Nanchang, Shenyang
2025-11-21
Recruiting
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
NCT07175493Autoimmune Cytopenia, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia, Evans Syndrome
DrugCM336
Keymed Biosciences Co.Ltd
Phase 1/2
158
Zhengzhou, Changzhi, Tianjin
2025-11-18
Recruiting
Henan Cancer Hospital
Observational
30
Zhengzhou
2025-11-18
Recruiting
GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma
NCT07209813Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer
DrugGKL-006
Beijing Gene Key Life Technology Co., Ltd
Phase 2
48
Beijing, Zhengzhou, Changsha, Nanjing, Nanchang, Hangzhou
2025-11-14
Recruiting
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing, Zhengzhou, Shenyang, Taiyuan
2025-11-12
Recruiting
Risen (Suzhou) Pharma Tech Co., Ltd.
Phase 3
312
Beijing, Zhengzhou
2025-11-12
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Guangzhou, Zunyi, Zhengzhou, Wuhan, Hohhot, Suzhou, Changchun, Shenyang
2025-11-11
Recruiting
BeOne Medicines
Phase 1
63
Beijing, Chongqing, Xiamen, Harbin, Zhengzhou, Shanghai, Chengdu, Hangzhou
2025-11-10
Recruiting
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis
NCT06902740Intracranial Atherosclerosis, Intracranial Artery Stenosis, Atherosclerotic Plaque
Peking Union Medical College Hospital
Phase 4
300
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2025-11-07
Active, closed
Suzhou HepaThera Biotech Co., Ltd.
Phase 2
60
Beijing, Fuzhou, Guangzhou, Qingyuan, Nanning, Zhengzhou, Nanjing, Zhenjiang
2025-11-05
By invitation
Nanfang Hospital, Southern Medical University
Not applicable
1,000
Guangzhou, Zhengzhou
2025-11-01
Not yet open
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
228
Beijing, Chongqing, Lanzhou, Guangzhou, Guiyang, Haikou, Harbin, Zhengzhou
2025-11
Recruiting
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Phase 3
406
Beijing, Xiamen, Guangzhou, Zunyi, Luoyang, Zhengzhou, Wuhan, Xiangtan
2025-10-31
Recruiting
AstraZeneca
Phase 3
100
Beijing, Changsha, Guangzhou, Linyi, Shandong, Wuhan, Zhengzhou
2025-10-30
Recruiting
Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.
NCT07569653Cytomegalovirus Infections, Cytomegalovirus Disease, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease
WeiShi
Phase 4
120
Beijing, Shijiazhuang, Zhengzhou, Jingzhou, Wuhan, Hohhot, Nanchang, Wenzhou
2025-10-30
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 2/3
360
Zhengzhou, Hangzhou
2025-10-24
Active, closed
Bristol-Myers Squibb
Phase 2/3
470
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Harbin, Luoyang, Zhengzhou
2025-10-23
Recruiting
MAXVAX Biotechnology Limited Liability Company
Phase 3
25,000
Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha, Xi'an, Jinan, Chengdu
2025-10-22
Recruiting
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
126
Beijing, Guangzhou, Zhengzhou, Wuhan
2025-10-21
Recruiting
Desflurane vs. Propofol for Cardiac Anesthesia
NCT07116733Cardiac Surgery, Coronary Artery Bypass Grafting
Xijing Hospital
Phase 3
3,560
Fuzhou, Cangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nanjin, Xi'an, Chengdu
2025-10-20
Recruiting
Nanjing Leads Biolabs Co.,Ltd
Phase 2
140
Hefei, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Xiangyang, Changsha
2025-10-20
Recruiting
Henan Cancer Hospital
Phase 2
30
Zhengzhou
2025-10-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Hefei, Beijing, Fujian, Fuzhou, Guangzhou, Nanning, Jiamusi, Zhengzhou
2025-10-08
Not yet open
Eye & ENT Hospital of Fudan University
Phase 4
360
Chongqing, Fuzhou, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Nanjing
2025-10-08
Not yet open
Xuhua Duan
Observational
2,000
Haikou, Xingtai, Dengzhou, Jiaozuo, Kaifeng, Luoyang, Shangqiu, Zhengzhou
2025-10-01
Not yet open
Haisco Pharmaceutical Group Co., Ltd.
Not applicable
200
Zhengzhou
2025-10-01
Recruiting
Bristol-Myers Squibb
Phase 2/3
470
Beijing, Fuzhou, Xiamen, Guangzhou, Zhengzhou, Changsha, Nanjing, Nantong
2025-09-30
Recruiting
Genentech, Inc.
Phase 2
224
Fuzhou, Xiamen, Guangzhou, Huizhou, Zhengzhou, Wuhan, Changchun, Binzhou
2025-09-29
Recruiting
A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
NCT07205315B-cell Acute Lymphoblastic Leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL), B-cell Non-Hodgkin's Lymphoma (B-NHL), Autoimmune Hemolytic Anemia (AIHA)
DrugGT801
Grit Biotechnology
Early Phase 1
28
Zhengzhou, Tianjin
2025-09-26
Recruiting
A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia
NCT07243379Clinical Characteristics and Treatment Outcomes of Malignant Tumor Cachexia, Multicenter Observational Study
DrugNanocrystalline Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 4
495
Zhengzhou
2025-09-25
Recruiting
PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
NCT07188610CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Suzhou
2025-09-25
Recruiting
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
NCT07141706Advanced/Metastatic Solid Tumors
DualityBio Inc.
Phase 1
253
Guangzhou, Harbin, Zhengzhou, Jinan
2025-09-23
Recruiting
Lee's Pharmaceutical Limited
Phase 1
100
Zhengzhou, Shanghai
2025-09-23
Recruiting
Shanghai Chest Hospital
Phase 2
96
Hefei, Beijing, Zhengzhou, Shanghai
2025-09-22
Recruiting
Abbisko Therapeutics Co, Ltd
Phase 2
86
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2025-09-22
Recruiting
A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)
NCT07154264Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DrugsBirelentinib·Venetoclax
Dizal Pharmaceuticals
Phase 2
66
Hefei, Beijing, Guangzhou, Zhengzhou, Wuhan, Yichang, Changsha, Changzhou
2025-09-22
Recruiting
Candid Therapeutics
Phase 1
44
Fuzhou, Guangzhou, Guiyang, Zhengzhou, Changchun, Shanghai, Taiyuan, Chengdu
2025-09-16
Not yet open
Disease-syndrome Characteristics of IPF
NCT07178392Idiopathic Pulmonary Fibrosis (IPF)
Henan University of Traditional Chinese Medicine
Observational
2,864
Zhengzhou
2025-09-15
Recruiting
InxMed (Shanghai) Co., Ltd.
Phase 3
400
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Gannan, Nanchang
2025-09-10
Recruiting
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
NCT06824103Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease
DrugRuxolitinib
Novartis Pharmaceuticals
Phase 4
50
Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-09-09
Recruiting
Henan University of Traditional Chinese Medicine
Not applicable
384
Zhengzhou
2025-09-08
Recruiting
QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
NCT06967103Breast Cancer, HR+/HER2- Breast Cancer
DrugLenvatinib
Henan Cancer Hospital
Phase 2
238
Zhengzhou
2025-09-08
Recruiting
Henan Cancer Hospital
Phase 1/2
14
Zhengzhou
2025-09-08
Not yet open
Reinforcement Learned Automated Anesthesia Systems During Painless Abortion
NCT07132151Painless Abortion, Artificial Intelligence (AI), Ciprofol
Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Not applicable
167
Fuzhou, Jinjiang, Quanzhou, Shenzhen, Zhengzhou, Chengdu, Chongqing
2025-09-08
Not yet open
Idiopathic Pulmonary Fibrosis Cohort of TCM
NCT07162870Idiopathic Pulmonary Fibrosis (IPF)
Henan University of Traditional Chinese Medicine
Observational
1,000
Zhengzhou
2025-09-05
Recruiting
Jiangsu HengRui Medicine Co., Ltd.
Phase 2
351
Harbin, Zhengzhou
2025-09-05
Recruiting
Ausper Biopharma Co., Ltd.
Phase 2
200
Beijing, Jilin City, Chongqing, Xiamen, Guangzhou, Shenzhen, Nanning, Zhengzhou
2025-09-04
Recruiting
Clinical Study of Cizutamig in Systemic Lupus Erythematosus
NCT07215663Systemic Lupus Erythematosus (SLE)
DrugCizutamig
Candid Therapeutics
Phase 1
47
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-09-04
Recruiting
Clinical Multimodal Surveillance of Respiratory Syndrome Pathogens
NCT07694648Respiratory Tract Infections (RTI), Respiratory Syndrome, Acute, Severe, Acute Respiratory Infections (ARIs)
Huashan Hospital
Observational
2,398
Beijing, Guangzhou, Zhuhai, Shijiazhuang, Harbin, Jiamusi, Shangqiu, Zhengzhou
2025-09-01
Recruiting
Plasma Biomarkers and Platelet Morphology of Extracorporeal CardioPulmonary Resuscitation
NCT07113769ExtraCorporeal Membrane Oxygenation (ECMO), Cardiac Arrest
Central China Fuwai Hospital of Zhengzhou University
Observational
130
Zhengzhou
2025-09-01
Not yet open
Shanghai Chest Hospital
Not applicable
465
Beijing, Zhengzhou, Nanjing, Ningbo, Shanghai
2025-09-01
Not yet open
Zhengzhou University
Phase 1/2
38
Zhengzhou
2025-09-01
Not yet open
A Study on Cardiopulmonary Exercise Tolerance Standards for Healthy Chinese Population
NCT07108296Oxygen Consumption, Cardiorespiratory Fitness
Affiliated Hospital of Changchun University of Chinese Medicine
Observational
4,620
Beijing, Quanzhou, Guangzhou, Nanning, Daqing, Harbin, Puyang, Zhengzhou
2025-09-01
Not yet open
Henan Cancer Hospital
Phase 2
280
Zhengzhou
2025-09-01
Recruiting
Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
NCT07170345Hepatocellular Carcinoma (HCC), Microvascular Invasion (MVI)
Chinese Academy of Sciences
Observational
400
Fuzhou, Guangzhou, Zhuhai, Nanning, Guiyang, Zhengzhou, Shenyang, Chengdu
2025-09-01
Recruiting
Zhigang Ren
Phase 3
120
Zhengzhou
2025-09-01
Not yet open
Ruijin Hospital
Phase 2
66
Beijing, Guangzhou, Shenzhen, Hebei, Zhengzhou, Wuhan, Changsha, Nanjing
2025-08-31
Recruiting
Henan Cancer Hospital
Phase 2
224
Zhengzhou
2025-08-30
Recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
192
Shenzhen, Nanning, Zhengzhou, Wuhan, Xiangyang, Changsha, Nanchang, Jinan
2025-08-29
Recruiting
Beijing Biostar Pharmaceuticals Co., Ltd.
Phase 2/3
778
Anyang, Guangzhou, Jinan, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
2025-08-28
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Beijing, Harbin, Zhengzhou
2025-08-28
Recruiting
BeOne Medicines
Phase 3
351
Hefei, Beijing, Xiamen, Anyang, Zhengzhou, Nanjing, Ganzhou, Shenyang
2025-08-27
Recruiting
Longhua Hospital
Not applicable
326
Beijing, Chongqing, Shenzhen, Shijiazhuang, Zhengzhou, Wuhan, Nanjing, Nanchang
2025-08-25
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
NCT07181473Lung Cancer (NSCLC), Prostate Cancer, Esophageal Cancer, Solid Tumor Malignancies
Phrontline Biopharma
Phase 1
200
Zhengzhou, Wuhan, Hangzhou, Shanghai
2025-08-25
Recruiting
Avistone Pharmaceutical（Ningbo）Co., LTD.
Phase 1/2
108
Zhengzhou, Shanghai
2025-08-22
Recruiting
Nuvation Bio Inc.
Phase 3
180
Beijing, Guangzhou, Nanning, Zhengzhou, Wuhan, Nanjing, Nantong, Nanchang
2025-08-21
Recruiting
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 2
75
Hefei, Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Zhengzhou
2025-08-21
Active, closed
Amgen
Phase 3
350
Beijing, Quanzhou, Harbin, Jiamusi, Zhengzhou, Nanchang, Jinan, Shanghai
2025-08-18
Recruiting
Chinese Academy of Sciences
Observational
200
Zhengzhou, Beijing, Shanghai
2025-08-15
Recruiting
Takeda
Phase 3
150
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-08-14
Recruiting
China National Center for Cardiovascular Diseases
Not applicable
4,900
Hefei, Beijing, Shenzhen, Shijiazhuang, Luoyang, Zhengzhou, Nanjing, Yangzhou
2025-08-08
Recruiting
Interventional Left Ventricular Assist System for PCI in CHIP Patients
NCT07053618High-Risk Percutaneous Coronary Intervention (High-risk PCI), Left Ventricular Assist Devices
Suzhou Hengruihongyuan Medical Technology Co. LTD
Not applicable
286
Beijing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Changsha, Suzhou, Nanchang
2025-08-06
Recruiting
Beijing Anzhen Hospital
Not applicable
4,100
Hefei, Beijing, Guangzhou, Shijiazhuang, Harbin, Luohe, Zhengzhou, Wuhan
2025-08-05
Recruiting
China National Center for Cardiovascular Diseases
Early Phase 1
3,160
Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Shanghai, Taiyuan, Chengdu
2025-08-05
Recruiting
Henan Institute of Cardiovascular Epidemiology
Not applicable
2,000
Zhengzhou
2025-08-01
Not yet open
29-Gene Liver Cancer Subtype and Immunotherapy Effectiveness
NCT07100236Primary Hepatocellular Carcinoma
Junjie Xu
Observational
350
Hefei, Chaoyang, Fuzhou, Guangzhou, Zhengzhou, Shanghai, Hangzhou, Wenzhou
2025-08-01
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
114
Zhengzhou, Nanchang, Shanghai
2025-08-01
Recruiting
Multi-Omics-Based Novel Thrombosis and Bleeding Markers and Risk Model for CHD
NCT07523880Thrombosis, Bleeding, Coronary Artery Disease (CAD)
Xueyan Zhao
Observational
12,154
Zhengzhou, Shenyang, Beijing
2025-08-01
Not yet open
Laparoscopic Adventitial Renal Denervation (RDN) for Refractory Hypertension
NCT07108829Refractory Hypertension or Drug-intolerant Hypertension
Henan Institute of Cardiovascular Epidemiology
Not applicable
10
Zhengzhou
2025-08
Not yet open
Ningbo Rongan Biological Pharmaceutical Co., Ltd.
Phase 3
3,000
Zhengzhou
2025-07-31
Recruiting
GeneSail Biotech (Shanghai) Co., Ltd.
Phase 1
32
Hefei, Fuzhou, Shenzhen, Zhengzhou, Changsha, Shanghai
2025-07-31
Recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2
97
Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan, Changsha
2025-07-30
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
298
Hefei, Beijing, Xiamen, Zhengzhou, Xuzhou, Nanchang
2025-07-30
Active, closed
Suzhou Junjing BioSciences Co., Ltd.
Phase 1/2
33
Zhengzhou
2025-07-28
Recruiting
AbbVie
Phase 3
120
Guangzhou, Zhengzhou, Changsha, Changchun, Shanghai, Hangzhou
2025-07-28
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
DrugMRG007
ArriVent BioPharma, Inc.
Phase 1
572
Beijing, Chongqing, Zhejiang, Heilongjiang, Zhengzhou, Wuhan, Changsha, Shandong
2025-07-25
Recruiting
Celcuity Inc
Phase 3
1,180
Beijing, Quanzhou, Luoyang, Xinxiang, Zhengzhou, Changsha, Shaoyang, Nanjing
2025-07-24
Recruiting
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
236
Beijin, Zhengzhou, Jinan, Chengdu, Shijia Zhuang
2025-07-24
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugBesremi
PharmaEssentia
Phase 3
160
Beijing, Chongqing, Guangdong, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing
2025-07-18
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
216
Beijing, Dongguan, Guangdong, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha
2025-07-15
Recruiting
Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta
NCT07025954Placenta Previa, Placenta Accreta Spectrum, Antepartum Bleeding, Emergency Cesarean Section
The Third Affiliated Hospital of Guangzhou Medical University
Not applicable
600
Guangzhou, Zhengzhou, Chengdu, Beijing, Chongqing
2025-07-12
Recruiting
Obstetrics & Gynecology Hospital of Fudan University
Observational
1,489
Lanzhou, Shenzhen, Haikou, Shijiazhuang, Zhengzhou, Dalian, Shenyang, Jinan
2025-07-09
Recruiting
MITRIS China Post Market Clinical Follow-up (PMCF) Study
NCT07059793Mitral Valve Replacement
Edwards Lifesciences
Observational
250
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Nanjing, Xi'an, Jinan
2025-07-08
Recruiting
Smith & Nephew, Inc.
Not applicable
105
Guangzhou, Zhengzhou, Nanjing, Changchun, Hangzhou
2025-07-02
Not yet open
DCB for CAD With Type 2 Diabetes
NCT07009938Coronary Artery Disease, Diabete Type 2
Shanghai 10th People's Hospital
Not applicable
1,000
Kaifeng, Luoyang, Zhengzhou, Shanghai, Yibin, Ningbo
2025-07-01
Recruiting
Heronova Pharmaceuticals
Phase 1
32
Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha, Jinan, Hangzhou
2025-06-30
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 2
50
Zhengzhou
2025-06-30
Recruiting
Henan Cancer Hospital
Phase 1/2
42
Zhengzhou
2025-06-25
Recruiting
Henan Cancer Hospital
Phase 3
812
Zhengzhou
2025-06-24
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
642
Hefei, Beijing, Lanzhou, Shantou, Harbin, Kaifeng, Puyang, Zhengzhou
2025-06-23
Recruiting
A Study in Children With Achondroplasia
NCT07301463Achondroplasia
Abbisko Therapeutics Co, Ltd
Observational
260
Beijing, Guangzhou, Zhengzhou, Wuhan, Shanghai, Chengdu, Hangzhou
2025-06-20
Active, closed
Novartis Pharmaceuticals
Phase 4
1,590
Anqing, Beijing, Chongqing, Longyan, Jiamusi, Zhengzhou, Baotou, Shenyang
2025-06-17
Active, closed
AbbVie
Phase 3
573
Hefei, Beijing, Chongqing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2025-06-17
Recruiting
Du Zhenggui
Not applicable
337
Fuzhou, Guangzhou, Anyang, Zhengzhou, Changsha, Hohhot, Suzhou, Nanchang
2025-06-17
Recruiting
ARX788 in HER2-positive Metastatic Breast Cancer Patients
NCT06663748HER2-positive, Metastatic Breast Cancer
DrugARX788
Henan Cancer Hospital
Phase 2
44
Zhengzhou
2025-06-16
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 2
78
Zhengzhou
2025-06-15
Not yet open
Henan University of Traditional Chinese Medicine
Not applicable
548
Zhengzhou
2025-06-15
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Alebund Pharmaceuticals
Phase 3
264
Beijing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Nantong, Wuxi
2025-06-13
Recruiting
Wecare Probiotics Co., Ltd.
Not applicable
100
Zhengzhou
2025-06-10
Recruiting
Novartis Pharmaceuticals
Observational
80
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nantong, Nanchang, Changchun
2025-06-10
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
480
Beijing, Chongqing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan
2025-06-04
Recruiting
The Hong Kong Polytechnic University
Observational
173
Zhengzhou, Shanghai, Shenzhen
2025-06-02
Recruiting
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
NCT06896422Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody, Glutathione
DrugGlutathione
The First Affiliated Hospital of Zhengzhou University
Phase 1
80
Zhengzhou
2025-06-01
Active, closed
Spatiotemporal Dynamics and Prognostic Value of the 18F-FDG PET Neuro-Metabolic Network
NCT07203495Lung Diseases, Endocrine Diseases, Gastrointestinal Diseases
The First Affiliated Hospital of Zhengzhou University
Observational
200
Zhengzhou
2025-06-01
Not yet open
Zhengzhou University
Phase 4
40
Zhengzhou
2025-05-30
Recruiting
Zhai Wenlong
Not applicable
30
Zhengzhou
2025-05-30
Recruiting
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
72
Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-05-29
Recruiting
Merck Sharp & Dohme LLC
Phase 2
144
Beijing, Chongqing, Fuzhou, Nanning, Zhengzhou, Nanjing, Shanghai
2025-05-28
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
80
Beijing, Guangzhou, Zhengzhou, Nanjing, Nanchang, Xi'an, Heze, Jinan
2025-05-26
Recruiting
Xijing Hospital
Observational
300
Wuwei, Shantou, Zhaoqing, Zhengzhou, Xi'an, Yan’an, Taiyuan, Chengdu
2025-05-26
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Phase 1
30
Hefei, Beijing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-05-23
Recruiting
Ningbo Rongan Biological Pharmaceutical Co., Ltd.
Phase 1
60
Zhengzhou
2025-05-23
Recruiting
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
220
Beijing, Haerbin, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Chengdu
2025-05-20
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
450
Guangzhou, Hangzhou, Hengyang, Nanning, Shenzhen, Taiyuan, Tianjin, Zhengzhou
2025-05-19
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Beijing, Chongqing, Fuzhou, Guangzhou, Zhuhai, Nanning, Zhengzhou, Wuhan
2025-05-13
Recruiting
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06801236Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Acerand Therapeutics (Hong Kong) Limited
Phase 1
88
Beijing, Hangzhou, Shanghai, Zhengzhou, Fuzhou
2025-05-12
Recruiting
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 1/2
56
Bengbu, Beijing, Tangshan, Zhengzhou, Nanchang, Xi’an, Tianjin
2025-05-12
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
172
Fuzhou, Guangzhou, Zhongshan, Nanning, Zhengzhou, Changsha
2025-05-07
Recruiting
BioNTech SE
Phase 1/2
594
Hefei, Beijing, Fuzhou, Nanning, Weihui, Zhengzhou, Jingzhou, Xiangyang
2025-05-02
Not yet open
Henan Cancer Hospital
Phase 1/2
32
Zhengzhou
2025-05-01
Recruiting
Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Not applicable
164
Anxi, Jinjiang, Xinzheng, Zhengzhou
2025-05-01
Recruiting
AstraZeneca
Phase 1
72
Beijing, Shanghai, Wuhan, Zhengzhou
2025-05-01
Not yet open
Henan Cancer Hospital
Not applicable
124
Zhengzhou
2025-05
Recruiting
Hoffmann-La Roche
Observational
800
Zhanjiang, Guangzhou, Kaifeng, Zhengzhou, Ürümqi, Beijing, Changsha, Changzhou
2025-04-30
Active, closed
Elpiscience (Suzhou) Biopharma, Ltd.
Phase 2
30
Beijing, Zhengzhou, Nanchang, Changchun, Jinan, Luoyang, Taiyuan, Taizhou
2025-04-30
Recruiting
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
300
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Wuhan
2025-04-28
Recruiting
Henan Cancer Hospital
Phase 2
180
Zhengzhou
2025-04-16
Recruiting
Henan University of Traditional Chinese Medicine
Not applicable
72
Zhengzhou
2025-04-15
Active, closed
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
NCT06900543Unresectable Hepatocellular Carcinoma
DrugSIRT
Chengdu New Radiomedicine Technology Co. LTD.
Phase 3
108
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Shenyang, Xi’an, Chengdu
2025-04-15
Recruiting
Henan Cancer Hospital
Phase 2
357
Zhengzhou
2025-04-15
Recruiting
5-Aminolevulinic Acid for Photodynamic Diagnosis of Malignant Glioma
NCT061604925-aminolevulinic Acid, Fluorescence-guided Resection, High-Grade Glioma (WHO III-IV)
Lee's Pharmaceutical Limited
Phase 3
79
Guangzhou, Zhengzhou
2025-04-14
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
72
Beijing, Chongqing, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Shenyang
2025-04-11
Recruiting
AbbVie
Observational
80
Guangzhou, Zhengzhou
2025-04-09
Recruiting
Beijing Anzhen Hospital
Not applicable
146
Hefei, Beijing, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2025-04-08
Recruiting
UTC Therapeutics Inc.
Not applicable
30
Zhengzhou
2025-04-03
Recruiting
Henan Cancer Hospital
Phase 2
146
Zhengzhou
2025-04-02
Not yet open
The Severity Assessment Model for AECOPD With Combination of Disease and Syndrome
NCT06918353Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Henan University of Traditional Chinese Medicine
Observational
1,500
Zhengzhou
2025-04-01
Recruiting
Sir Run Run Shaw Hospital
Phase 2
70
Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou, Wenzhou
2025-04-01
Recruiting
Allogeneic γδT Cells in Glioblastoma
NCT07144735Glioblastoma (GBM), Glioblastoma Multiforme (GBM)
Peking University Third Hospital
Not applicable
18
Beijing, Zhengzhou
2025-04-01
Not yet open
Henan Cancer Hospital
Phase 4
203
Zhengzhou
2025-04
Not yet open
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
188
Zhengzhou
2025-04
Not yet open
Betta Pharmaceuticals Co., Ltd.
Phase 2
100
Hefei, Lanzhou, Dongguan, Foshan, Guangzhou, Baoding, Harbin, Zhengzhou
2025-03-31
Recruiting
Gritgen Therapeutics Co., Ltd.
Phase 3
50
Hefei, Beijing, Lanzhou, Guangzhou, Tangshan, Zhengzhou, Wuhan, Changsha
2025-03-31
Recruiting
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
NCT06932068HER2 Negative, Low PD-L1 Expressing, Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
DrugsIparomlimab and Tuvonralimab·Lenvatinib
Qilu Hospital of Shandong University
Phase 2
77
Zhengzhou, Binzhou, Dezhou, Dongying, Jinan, Jining, Liaocheng, Linyi
2025-03-26
Active, closed
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 3
40
Hefei, Lanzhou, Guangzhou, Shenzhen, Nanning, Tangshan, Harbin, Zhengzhou
2025-03-26
Recruiting
Nanjing RegeneCore Biotech Co., Ltd.
Phase 1
71
Hefei, Guangzhou, Shenzhen, Guilin, Nanning, Baoding, Tangshan, Zhengzhou
2025-03-25
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 2
276
Zhengzhou
2025-03-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Bengbu, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Wuhan, Xiangyang
2025-03-16
Not yet open
Wecare Probiotics Co., Ltd.
Not applicable
90
Zhengzhou
2025-03-15
Recruiting
Xiangbo Wan
Phase 2
30
Zhengzhou
2025-03-12
Recruiting
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
55
Wuhu, Xiamen, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Zhengzhou
2025-03-12
Not yet open
Wecare Probiotics Co., Ltd.
Not applicable
40
Zhengzhou
2025-03-10
Recruiting
Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer
NCT07104149Female, Age ≥ 18 Years Old, No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy, ECOG Score of 0-1, Histologically Confirmed Cervical Cancer, FIGO Stage IB3, IIA2, IIB, IIIC, and Assessed by the Researcher as Resectable Lesion
DrugsCadonilimab·Cisplatin
The First Affiliated Hospital of Zhengzhou University
Phase 2
29
Zhengzhou
2025-03-10
Not yet open
Wecare Probiotics Co., Ltd.
Not applicable
45
Zhengzhou
2025-03-10
Not yet open
Wecare Probiotics Co., Ltd.
Not applicable
40
Zhengzhou
2025-03-10
Active, closed
Henan Cancer Hospital
Phase 2
30
Zhengzhou
2025-03-08
Recruiting
Suzhou Genhouse Bio Co., Ltd.
Phase 1
200
Beijing, Fuzhou, Xiamen, Lanzhou, Guangzhou, Nanning, Guiyang, Zhengzhou
2025-03-07
Recruiting
AbbVie
Phase 1/2
252
Beijing, Fuzhou, Liuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2025-03-06
Recruiting
BeOne Medicines
Phase 3
300
Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Xuzhou
2025-03-05
Recruiting
JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
NCT06890065B Acute Lymphoblastic Leukemia, B-Non Hodgkin Lymphoma
DrugJY231
Shenzhen Genocury Biotech Co., Ltd.
Not applicable
20
Zhengzhou
2025-03-01
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 2
170
Zhengzhou
2025-03-01
Not yet open
Xuhua Duan
Observational
59
Dengzhou, Jiaozuo, Kaifeng, Luoyang, Shangqiu, Zhengzhou, Zhoukou
2025-03-01
Not yet open
Ying Gao
Observational
4,460
Lanzhou, Harbin, Zhengzhou, Nanjing, Xuzhou, Changchun, Jining, Xian
2025-03-01
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 2
170
Zhengzhou
2025-03-01
Active, closed
Peking University People's Hospital
Not applicable
105
Beijing, Zhengzhou
2025-03-01
Recruiting
The First Affiliated Hospital with Nanjing Medical University
Not applicable
980
Zhengzhou, Changzhou, Nanjing, Suzhou, Xi’an
2025-03-01
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 2
276
Zhengzhou
2025-03-01
Recruiting
Fudan University
Phase 2
208
Fuzhou, Xiamen, Lanzhou, Zhengzhou, Huaian, Jinan, Taian, Shanghai
2025-03-01
Active, closed
Qiming Wang
Observational
500
Zhengzhou
2025-03-01
Recruiting
Takeda
Phase 3
171
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-02-27
Recruiting
Lepu Medical Technology (Beijing) Co., Ltd.
Not applicable
213
Beijing, Chongqing, Xiamen, Lanzhou, Shenzhen, Zhengzhou, Hohhot, Yinchuan
2025-02-25
Recruiting
Henan Cancer Hospital
Observational
20
Zhengzhou
2025-02-21
Recruiting
Henan Cancer Hospital
Observational
40
Zhengzhou
2025-02-20
Active, closed
LG Chem
Phase 4
248
Zhengzhou
2025-02-15
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Wuxi, Changchun, Beijing
2025-02-07
Active, closed
Genmab
Phase 3
584
Guangzhou, Xi'an, Changchun, Hanzhou, Shanghai, Tianjin, Zhengzhou
2025-02-07
Recruiting
BeOne Medicines
Phase 1
120
Guangzhou, Zhengzhou, Shanghai, Tianjin, Hangzhou
2025-02-04
Recruiting
Chronic Airway Disease and Multimorbidity Cohort
NCT06798077Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchiectasis
China-Japan Friendship Hospital
Observational
2,000
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Shenyang, Xi'an, Shanghai
2025-02-01
Not yet open
Henan Cancer Hospital
Observational
55
Zhengzhou
2025-02-01
Recruiting
Beijing Chao Yang Hospital
Not applicable
200
Beijing, Guangzhou, Zhengzhou, Changsha, Shenyang, Shanghai, Taiyuan, Hangzhou
2025-02-01
Not yet open
Fuling Zhou
Phase 1/2
42
Zhengzhou, Wuhan, Xianning
2025-02
Not yet open
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
68
Fuzhou, Guangzhou, Zhengzhou, Nanchang, Tianjin, Kunming
2025-02
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Beijing, Guangzhou, Jinan, Tianjin, Zhengzhou
2025-01-30
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
135
Bengbu, Wuwei, Guangzhou, Huizhou, Harbin, Luoyang, Nanyang, Zhengzhou
2025-01-28
Recruiting
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1/2
84
Beijing, Fuzhou, Foshan, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang
2025-01-23
Recruiting
Shanghai Institute Of Biological Products
Phase 1
120
Zhengzhou
2025-01-22
Recruiting
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2
300
Harbin, Zhengzhou
2025-01-21
Recruiting
AbbVie
Phase 2
150
Beijing, Fuzhou, Nanning, Harbin, Zhengzhou, Wuhan, Nanchang, Xi'an
2025-01-20
Not yet open
Henan Cancer Hospital
Phase 2
250
Luoyang, Xinxiang, Zhengzhou
2025-01-15
Recruiting
Fortvita Biologics (USA)Inc.
Phase 1
250
Hefei, Beijing, Fuzhou, Nanning, Harbin, Anyang, Luoyang, Zhengzhou
2025-01-10
Recruiting
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
163
Beijing, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Tianjin
2025-01-08
Recruiting
CASI pharmaceuticals, Inc.
Phase 1/2
75
Tangshan, Zhengzhou, Nanchang, Jinan, Tianjin, Kunming
2025-01-03
Recruiting
Sun Yat-sen University
Phase 2
76
Lanzhou, Guangzhou, Zhengzhou
2025-01-03
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
358
Shijiazhuang, Zhengzhou, Jinan, Chengdu
2025-01-01
Recruiting
Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
NCT07187908Primary/Secondary Prevention, High Risk for Febrile Neutropenia of Chemotherapy Regimens, Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia
DrugEfbemalenograstim alfa
Henan Cancer Hospital
Phase 2
1,076
Zhengzhou
2025-01-01
Recruiting
Early Vitrectomy vs PRP in Early Proliferative Diabetic Retinopathy
NCT07586787Proliferative Diabetic Retinopathy (PDR)
Xiamen Ophthalmology Center Affiliated to Xiamen University
Not applicable
100
Beijing, Xiamen, Zhengzhou, Nanjing, Dalian
2025-01-01
Recruiting
China-Japan Friendship Hospital
Not applicable
400
Xingtai, Zhengzhou, Baotou, Jinan, Datong, Kunming, Beijing
2025-01-01
Recruiting
Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden
NCT06769256ST-segment Elevation Myocardial Infarction (STEMI)
DrugTirofiban
Henan Institute of Cardiovascular Epidemiology
Phase 4
300
Zhengzhou
2025-01-01
Recruiting
Henan Institute of Cardiovascular Epidemiology
Not applicable
2,146
Zhengzhou
2025-01-01
Not yet open
InnoBM Pharmaceuticals Co., Ltd.
Phase 3
228
Bengbu, Anyang, Zhengzhou, Nanjing, Lishui, Guangzhou, Lanzhou, Luoyang
2025-01
Active, closed
Juan Li
Observational
400
Zhengzhou
2024-12-30
Recruiting
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
190
Hefei, Fuzhou, Zhengzhou, Changsha, Nanchang, Jinan, Hangzhou
2024-12-30
Not yet open
Henan Cancer Hospital
Observational
100
Zhengzhou
2024-12-30
Not yet open
Henan Cancer Hospital
Observational
80
Zhengzhou
2024-12-28
Not yet open
Application of Antiosteoporosis Therapy in Osteolysis
NCT05617846Limb; Fusion, Complication
Henan Cancer Hospital
Observational
100
Zhengzhou
2024-12-28
Active, closed
Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline Dystrophy
NCT06743646Bietti Crystalline Corneoretinal Dystrophy, Bietti Crystalline Dystrophy
DrugZVS101e
Chigenovo Co., Ltd
Phase 3
63
Beijing, Guangzhou, Zhengzhou, Chengdu, Tianjin
2024-12-27
Recruiting
Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors
NCT06566079Malignant Mesothelioma, Metastatic Malignant Solid Tumor, Advanced Solid Tumor
InSilico Medicine Hong Kong Limited
Phase 1/2
160
Zhengzhou, Shanghai, Beijing, Guangzhou
2024-12-27
Active, closed
Amgen
Phase 2
61
Beijing, Fuzhou, Zhengzhou, Wuhan, Changsha, Changchun, Jinan, Shanghai
2024-12-26
Recruiting
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
DrugsICP-248·Azacitidine
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
266
Hefei, Beijing, Chongqing, Guangzhou, Zhengzhou, Wuhan, Suzhou, Nanchang
2024-12-18
Recruiting
Nanjing IASO Biotechnology Co., Ltd.
Observational
1,500
Beijing, Tianjin, Wuhan, Zhengzhou
2024-12-15
Recruiting
Hutchmed
Phase 3
412
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha
2024-12-12
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
150
Guangzhou, Shenzhen, Zhengzhou, Nanjing, Nanchang, Shanghai, Xi’an, Chengdu
2024-12-09
Recruiting
Peking University People's Hospital
Observational
163
Beijing, Wuhan, Zhengzhou
2024-12-09
Recruiting
Henan Cancer Hospital
Observational
709
Zhengzhou
2024-12-04
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 4
30
Zhengzhou
2024-12-04
Not yet open
Mingzhi Zhang
Phase 1
30
Zhengzhou
2024-12-01
Not yet open
Clinical Observation on the Safety and Efficacy of Cardonilmab in the Treatment of Second-line and Above Advanced Melanoma and Advanced Renal Cancer
NCT06670300Participants Who Had Received Second-line or Higher Advanced Melanoma and Advanced Renal Cancer
YongZhang
Phase 2
20
Zhengzhou
2024-12-01
Not yet open
Henan University of Traditional Chinese Medicine
Not applicable
2,312
Zhengzhou
2024-12
Recruiting
Nuvation Bio Inc.
Phase 3
194
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Nanning, Shijiazhuang, Zhengzhou
2024-11-27
Recruiting
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
334
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Langfang, Haerbin, Zhengzhou
2024-11-22
Recruiting
A Study of EH002 Gene Therapy for Otoferlin Gene Mutation-mediated Hearing Loss
NCT06722170DFNB9, Congenital Hearing Loss, Hearing Loss, Sensorineural
Yilai Shu
Not applicable
24
Zhengzhou, Shanghai
2024-11-22
Recruiting
Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors
NCT06666270Advanced Solid Cancer, Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
Phase 1
30
Zhengzhou, Shanghai
2024-11-21
Recruiting
Novabio Therapeutics
Phase 1
12
Zhengzhou
2024-11-21
Recruiting
Mingzhi Zhang
Phase 1/2
80
Zhengzhou
2024-11-20
Recruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
42
Bozhou, Chuzhou, Hefei, Ma’anshan, Wuhu, Harbin, Zhengzhou, Wuhan
2024-11-14
Active, closed
BeOne Medicines
Phase 2
94
Fuzhou, Zhengzhou, Changzhou, Nanjing, Shanghai, Hangzhou
2024-11-14
Active, closed
AbbVie
Observational
110
Beijing, Xiamen, Guangzhou, Zhengzhou, Wuhan, Dalian, Xi'an, Qingdao
2024-11-13
Recruiting
A Phase 2 Clinical Study of ABSK061 and ABSK043
NCT06632262HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
DrugsABSK061·ABSK043·Folfox
Abbisko Therapeutics Co, Ltd
Phase 2
202
Guiyang, Shijiazhuang, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan
2024-11-13
Active, closed
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
60
Fuyang, Hefei, Chongqing, Lanzhou, Guangzhou, Nanning, Zhengzhou, Changsha
2024-11-12
Recruiting
An Observational Study of Coronary Microvascular Disease of China
NCT06676137Coronary Microvascular Disease
Henan Institute of Cardiovascular Epidemiology
Observational
500
Zhengzhou
2024-11-11
By invitation
The First Affiliated Hospital of Zhengzhou University
Phase 2
50
Zhengzhou
2024-11-08
Recruiting
The First People's Hospital of Changzhou
Phase 3
200
Zhengzhou, Changzhou
2024-11-08
Recruiting
Ranok Therapeutics (Hangzhou) Co., Ltd.
Phase 1/2
152
Nanning, Zhengzhou, Wuhan, Hangzhou, Shanghai
2024-11-08
Recruiting
Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC
NCT06817525Triple-negative Breast Cancer
Henan Cancer Hospital
Phase 2
64
Zhengzhou
2024-11-06
Active, closed
Merck Sharp & Dohme LLC
Phase 1/2
180
Hefei, Fuzhou, Xiamen, Guangzhou, Nanning, Zhengzhou, Shanghai, Taiyuan
2024-11-03
Recruiting
Longitudinal Cohort of Thrombosis and Hemostasis Diseases
NCT06727669Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura, Hemophilia A, Acquired, Disseminated Intravascular Coagulation
Peking University People's Hospital
Observational
3,000
Beijing, Zhengzhou, Chongqing
2024-11-01
Not yet open
Shanghai 10th People's Hospital
Not applicable
2,000
Kaifeng, Zhengzhou, Shanghai
2024-11-01
Not yet open
Abnormal Glucose Tolerance in Allogeneic Hematopoietic Stem Cell Transplantation
NCT06704542ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Diabetes Mellitus, Impaired Fasting Glucose
Ruijin Hospital
Observational
1,000
Zhengzhou, Wuhan, Shanghai, Hangzhou, Tianjin
2024-11
Not yet open
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
120
Beijing, Nanning, Zhengzhou, Shanghai, Hangzhou
2024-11
By invitation
Yongxu Jia
Observational
200
Zhengzhou
2024-10-31
Recruiting
Henan Cancer Hospital
Not applicable
26
Zhengzhou
2024-10-30
Active, closed
Daiichi Sankyo
Phase 1/2
137
Changchun, Hangzhou, Harbin, Jiamusi, Shanghai, Tiyuan, Zhengzhou
2024-10-30
Recruiting
Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine
NCT06617715Pneumococcal Infectious Disease
DrugPrevnar
Sinovac Life Sciences Co., Ltd.
Phase 3
3,080
Zhengzhou
2024-10-23
Recruiting
Pfizer
Phase 3
900
Wuhu, Beijing, Fuzhou, Guangzhou, Shantou, Guilin, Xinxiang, Zhengzhou
2024-10-22
Recruiting
Santen Pharmaceutical Co., Ltd.
Phase 3
180
Hefei, Beijing, Shantou, Guiyang, Zhengzhou, Ha’erbin, Wuhan, Xiangyang
2024-10-22
Recruiting
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
NCT06730373HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma
DrugsTeysuno·Disitamab Vedotin·Trastuzumab·Adrucil
Qilu Hospital of Shandong University
Phase 2
110
Zhengzhou, Binzhou, Dongying, Jinan, Jining, Liaocheng, Linyi, Qingdao
2024-10-17
Recruiting
The First Affiliated Hospital of Zhengzhou University
Phase 1/2
29
Zhengzhou
2024-10-10
Active, closed
Novartis Pharmaceuticals
Phase 2
201
Nanning, Zhengzhou, Chengdu, Ningbo, Beijing, Tianjin
2024-10-09
Recruiting
BeOne Medicines
Phase 1
310
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou
2024-10-03
By invitation
Influencing Factors and Outcomes of DCB Angioplasty
NCT06620458Coronary Artery Disease
Henan Institute of Cardiovascular Epidemiology
Observational
5,000
Zhengzhou
2024-10-01
By invitation
Yingjuan Zheng
Phase 2
230
Zhengzhou
2024-10-01
By invitation
Yingjuan Zheng
Phase 2
216
Zhengzhou
2024-10-01
Not yet open
Respiratory Disease Cohort Studies of Chinese Medicine for COPD(RESEARCH-COPD)
NCT06577701Chronic Obstructive Pulmoriary Disease (COPD), Preserved Ratio Impaired Spirometry (PRISM)
Henan University of Traditional Chinese Medicine
Observational
10,000
Zhengzhou
2024-10-01
Recruiting
Zhengzhou University
Phase 4
20
Zhengzhou
2024-09-30
Not yet open
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
126
Shijiazhuang, Zhengzhou, Jinan, Chengdu
2024-09-30
Active, closed
AbbVie
Phase 1
31
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanchang, Shenyang, Hangzhou
2024-09-30
Recruiting
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
NCT06580301B-cell Acute Lymphoblastic Leukemia
DrugYK012
Excyte Biopharma Ltd
Phase 1/2
46
Guangzhou, Guiyang, Zhengzhou, Xuzhou, Nanchang, Changchun, Dalian, Shenyang
2024-09-25
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
160
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, Ürümqi, Hangzhou
2024-09-20
Not yet open
Henan University of Traditional Chinese Medicine
Observational
1,016
Zhengzhou
2024-09-20
Not yet open
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
60
Hefei, Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Nanchang
2024-09-20
Active, closed
Amgen
Phase 1
49
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changchun, Chengdu, Beijing
2024-09-17
By invitation
Sinovac (Dalian) Vaccine Technology Co., Ltd.
Phase 4
414
Zhengzhou
2024-09-16
Recruiting
Wayshine Biopharm, Inc.
Phase 1/2
100
Hefei, Beijing, Guangzhou, Zhengzhou, Jinan, Shanghai, Chengdu, Tianjin
2024-09-04
Rows per page Showing 1–500 of 931
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/zhengzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 08 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 931 of those studies with a site in Zhengzhou.

How many clinical trials are recruiting in Zhengzhou?

562 of the 931 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:17 UTC sync. A further 156 have not yet opened recruitment, 200 are active but closed to new participants, and 13 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Zhengzhou), 931 studies
PhaseStudiesRecruitingShare
Phase 31998021.4%
Phase 219412220.8%
Observational1247113.3%
Phase 1/21249613.3%
Not applicable1207312.9%
Phase 11138312.1%
Phase 435193.8%
Phase 2/31291.3%
Early Phase 11091.1%

Most active sponsors

Lead sponsors with the most studies (Zhengzhou)
Lead sponsorStudiesRecruiting
Henan Cancer Hospital7549
The First Affiliated Hospital of Zhengzhou University3825
Merck Sharp & Dohme LLC2814
AbbVie217
Novartis Pharmaceuticals206
Bristol-Myers Squibb197
Henan University of Traditional Chinese Medicine195
BeOne Medicines1510
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.1510
AstraZeneca149
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.